16 October 2015 - Basilea Pharmaceutica Ltd. announced today that the European Commission has approved the antifungal isavuconazole for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.

For more details, go to: http://www.basilea.com/News-and-Media/Basilea-announces-that-European-Commission-approves-isavuconazole-CRESEMBA-as-a-treatment-for-invasive-aspergillosis-and-mucormycosis-in-the-European-Union/1c973f43-6bf6-e9c0-acc7-a28994a4cbc3